Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Retrospective: Pharmaceutical Blockbuster Trends Since 1996
- Methodology
- Trends in the Number of Blockbusters, 1996-2006
- Trends in the Type of Drugs Achieving Blockbuster Status, 1996-2006
- Trends in Companies Producing Blockbusters, 1996-2006
- Trends in the Therapeutic Areas of Blockbusters, 1996-2006
- Examples of Recently Failed, Highly Anticipated Blockbusters
- Sanofi -Aventis' s Acomplia (Rimonabant)
- Pfi zer' s Torcetrapib
- Neurochem' s Alzhemed (Tramiprosate)
- Upcoming Patent Effects on Current Blockbusters
- Review of Emerging Blockbusters
- Emerging Blockbusters to Treat Metabolic Disease
- Novartis' s Galvus (Vildagliptin)
- Merck' s Cordaptive (ER niacin and laropiprant)
- Emerging Blockbusters for Cardiovascular Disease
- Novartis' s Exforge (Amlodipine & Valsartan)
- Emerging Blockbusters for Oncology
- GlaxoSmithKline' s Tykerb (Lapatinib)
- Emerging Blockbusters for Infectious Diseases
- Merck' s Isentress (Raltegravir)
- Emerging Blockbusters for Psychiatric Disorders
- Wyeth' s Pristiq (Desvenlafaxine)
- Conclusion
Tables
- 1. Top Blockbuster Companies, 1996-2000
- 2. Top Blockbuster Companies, 2001-2006
- 3. Total Number of Blockbusters by Company, 1996-2006
- 4. Patent Expiries in Major Markets of the 10 Top-Selling 2006 Blockbusters
- 5. Development Status and Anticipated Launch Year of Emerging Blockbusters
Figures
- 1. Growth in Number of Blockbusters Worldwide, 1996-2006
- 2. Select Companies' Late-Stage Pipelines vs. Anticipated 2012 Patent
Expiries
- 3. Number of Conventional-Technology Blockbusters vs. Biotechnology
Blockbusters, 1996-2006
- 4. Number of Blockbusters by Therapeutic Area, 1996-2000
- 5. Number of Blockbusters by Therapeutic Area, 2001-2006
- 6. Prevalent Cases of Select Metabolic Diseases in the Major Markets, 2006
- 7. Major-Market Value of Select Metabolic Disease Segments, 2006
- 8. Major-Market Value of Breast and Renal Cancer Therapies, 2005
- 9. Prevalent Cases of Breast and Renal Cancer in the Major Markets, 2006
- 10. Major-Market Value of Bipolar and Major Depression Therapies, 2005
- 11. Prevalent Cases of Bipolar and Major Depression in the Major Markets,
2006
- A. Projected Growth in Biologics Sales, 2001-2010
Expert Commentaries
- Exubera: What Went Wrong?
- Biologics Blockbusters-Decreased Vulnerability to Biosimilars and "Me Too"
Drugs Portends Better Prospects for Blockbuster Sales Sustainability
- Big Pharma' s Interest in Biotech: Will the Trend Continue or Do Troubles
Lie Ahead?
|
Related Report
|
View Cart
